The significant contribution of the early Apln-CreER lineage to the tumour vasculature several days later, combined with APLN’s restricted expression in the angiogenic front at that later stage, suggested that APLN is enriched in, and therefore Apln-CreER labels, sprouting angiogenic ECs. The gene discussed is APLN; the disease is neoplasm.